ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,870.62
-1.32%
US Tech 100
19,880.00
-2.30%
Dow Jones
43,444.99
-0.70%
Brent Oil
71.25
0.50%
Bitcoin
91,355.03
0.32%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Viridian Therapeutics Inc (VRDN)

  7. Viridian Therapeutics Inc (VRDN) News

Viridian Therapeutics Inc

Viridian Therapeutics Inc (VRDN)

Viridian Metals Inc
20.14
-1.50
(-6.93%)
Closed November 16 4:00PM
Delayed by 15 minutes
19.00
-1.14
(-5.66%)
After Hours: 7:59PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

VRDN News

Official News Only

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
VRDN (-6.93%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
VRDN (-6.93%)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Edgar (US Regulatory)
November 14 2024
VRDN (-6.93%)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
November 12 2024
VRDN (-6.93%)

Form 8-K - Current report
Edgar (US Regulatory)
November 12 2024
VRDN (-6.93%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 30 2024
VRDN (-6.93%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 30 2024
VRDN (-6.93%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 17 2024
VRDN (-6.93%)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Edgar (US Regulatory)
September 17 2024
VRDN (-6.93%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
September 13 2024
VRDN (-6.93%)

Form 8-K - Current report
Edgar (US Regulatory)
September 12 2024
VRDN (-6.93%)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Edgar (US Regulatory)
September 10 2024
VRDN (-6.93%)

VRDN Discussion

View Posts
Monksdream Monksdream 2 months ago
VRDN more upside possible

👍️0
it_happens it_happens 2 months ago
Touched 20s today. Maybe it will stay above 20 tomorrow
👍️0
power11 power11 2 months ago
LOW 20'S BY WEEKEND IMO !!!
GOOD LUCK
👍️0
it_happens it_happens 2 months ago
Good news. I don't think that this is merely a one-day runner.
👍️0
power11 power11 2 months ago
BTIG RESEARCH ADJUST PRICE TARGET TO 56 FROM 46; STRONG BUY !!
👍️0
it_happens it_happens 2 months ago
Over 15 and having a good day today
👍️0
Monksdream Monksdream 2 months ago
VRDN under $15
👍️0
Apprentice Apprentice 3 years ago
I put into it a lot of $
423 shares!
👍️0
Apprentice Apprentice 3 years ago
It just doesn't want to move above $18
Yet, it's not diving much either.
What do you think at this point? Sell temporarily and by later low?
My average is too high @17.76 !
👍️0
crudeoil24 crudeoil24 3 years ago
Viridian Therapeutics, Inc., formerly Miragen Therapeutics, Inc., is a biotechnology company. The Company is engaged in developing multiple product candidates to treat patients who suffer from thyroid eye disease (TED), a debilitating orphan disease, and has early-stage programs focused on other targets and indications. Its lead candidate, VRDN-001, is a clinical-stage anti-IGF-1R monoclonal antibody (mAb) that is under development for thyroid eye disease (TED). The Company's TED pipeline also includes VRDN-002 and VRDN-003. Its other programs include VRDN-004, which is under development for undisclosed rare orphan disease, and VRDN-005, which is under development for tick-borne disease (TBD). The Company also out licenses its programs.
👍️0

Your Recent History

NASDAQ
VRDN
Viridian Therapeutics
TSXV
MMS
Macarthur Minerals
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved